Pre-Open Stock Movers: Antares Pharma, Inc. (NASDAQ:ATRS) 49% HIGHER; Halozyme Therapeutics, Inc. (NASDAQ:HALO) agreed to acquire the company for $5.60 per share in cash, or $960...
After-Hours Stock Movers: NanoString Technologies Inc (NASDAQ:NSTG) 29% LOWER; announced preliminary total product and service revenue of approximately $31 million for the first...
Trovagene, Inc. (NASDAQ:TROV) announced successful completion of a phase Ib dose escalation study evaluating its sole pipeline candidate, onvansertib, in combination with...
San Diego, CA-based TrovaGene Inc. (NASDAQ:TROV) , a molecular diagnostic company, recently announced encouraging data pertaining to its Precision Cancer Monitoring (PCM)...
TrovaGene Inc. (NASDAQ:TROV) is expected to release second-quarter 2016 results on Aug 4. Last quarter, the company reported a loss of 38 cents per share, which was wider than...
Cardiff Oncology Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatment for cancer patients. Its drug candidate onvansertib, is a polo-like kinase 1 (PLK1) adenosine triphosphate (ATP) competitive inhibitor with the combination of chemotherapy and targeted therapeutics. Its clinical trial includes TROV-054, CRDF-001 and TROV-053. TROV-054 is a Phase I b/2 open-label clinical trial of onvansertib in combination with FOLFIRI (folinic acid, fluorouracil, and irinotecan) and Avastin (bevacizumab). TROV-053 is a Phase II open-label clinical trial of onvansertib in combination with Zytiga (abiraterone acetate)/prednisone. CRDF-001 is a Phase 2 open-label multi-center clinical trial of onvansertib in combination with nanoliposomal irinotecan, leucovorin, and fluorouracil for second line treatment of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).
|Average||8.000 (+288.350% Upside)|
|No. of Analysts||3|